{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:28:10Z","timestamp":1793287690292,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ygyno.2026.06.021","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T17:16:35Z","timestamp":1783703795000},"page":"132-137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Response to mirvetuximab soravtansine and weekly paclitaxel based on treatment sequencing in platinum-resistant ovarian cancer: Does order matter?"],"prefix":"10.1016","volume":"211","author":[{"given":"Paulina J.","family":"Haight","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia C.","family":"Sakach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M.","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floor J.","family":"Backes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Cohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry J.","family":"Copeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey M.","family":"Cosgrove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa I.","family":"Nagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert T.","family":"Neff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"O'Malley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2026.06.021_bb0005","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.ygyno.2026.06.021_bb0010","doi-asserted-by":"crossref","first-page":"R303","DOI":"10.1530\/ERC-17-0336","article-title":"Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment","volume":"25","author":"van Zyl","year":"2018","journal-title":"Endocr. Relat. Cancer"},{"issue":"4","key":"10.1016\/j.ygyno.2026.06.021_bb0015","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3892\/or.2022.8293","article-title":"Molecular mechanisms of platinum-based chemotherapy resistance in ovarian cancer","volume":"47","author":"Yang","year":"2022","journal-title":"Oncol. Rep."},{"issue":"10","key":"10.1016\/j.ygyno.2026.06.021_bb0020","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1023\/A:1008240421028","article-title":"Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients","volume":"8","author":"Eisenhauer","year":"1997","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2026.06.021_bb0025","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.2165\/11591720-000000000-00000","article-title":"Management strategies for recurrent platinum-resistant ovarian Cancer","volume":"71","author":"Naumann","year":"2011","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.ygyno.2026.06.021_bb0030","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jamaoncol.2023.0197","article-title":"Advances in ovarian cancer care and unmet treatment needs for patients with platinum resistance: a narrative review","volume":"9","author":"Richardson","year":"2023","journal-title":"JAMA Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.06.021_bb0035","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ygyno.2014.02.038","article-title":"\u201cPlatinum resistant\u201d ovarian cancer: what is it, who to treat and how to measure benefit?","volume":"133","author":"Davis","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.06.021_bb0040","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ygyno.2005.10.036","article-title":"Phase II trial of weekly paclitaxel (80 mg\/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic oncology group study","volume":"101","author":"Markman","year":"2006","journal-title":"Gynecol. Oncol."},{"issue":"14","key":"10.1016\/j.ygyno.2026.06.021_bb0045","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2026.06.021_bb0050","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.1997.15.6.2183","article-title":"Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer","volume":"15","author":"ten Bokkel","year":"1997","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.ygyno.2026.06.021_bb0055","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2026.06.021_bb0060","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO-ESGO ovarian cancer consensus conference working group. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.06.021_bb0065","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ygyno.2021.08.032","article-title":"Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: a multicenter, randomized, controlled, open-label phase 3 study (CORAIL)","volume":"163","author":"Gaillard","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"17","key":"10.1016\/j.ygyno.2026.06.021_bb0070","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.2217\/fon-2017-0646","article-title":"Forward I: a phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer","volume":"14","author":"Moore","year":"2018","journal-title":"Future Oncol."},{"issue":"32","key":"10.1016\/j.ygyno.2026.06.021_bb0075","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1200\/JCO.2015.63.1408","article-title":"Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III AURELIA trial","volume":"33","author":"Poveda","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.ygyno.2026.06.021_bb0080","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FRalpha-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ygyno.2026.06.021_bb0085","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/ijgc-2023-004924","article-title":"Mirvetuximab soravtansine-gynx: first antibody\/antigen-drug\/conjugate (ADC) in advanced or recurrent ovarian cancer","volume":"34","author":"Bogani","year":"2024","journal-title":"Int. J. Gynecol Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2026.06.021_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102016","article-title":"Mirvetuximab soravtansine in the ovarian cancer treatment landscape: influence of prior taxane exposure on outcomes","volume":"35","author":"Smick","year":"2025","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2026.06.021_bb0095","doi-asserted-by":"crossref","first-page":"S1582","DOI":"10.1016\/j.annonc.2025.09.049","article-title":"Pembrolizumab vs placebo plus weekly paclitaxel +\/\u2212 bevacizumab in platinum-resistant recurrent ovarian cancer: results from the randomized double-blind phase III ENGOT-ov65\/KEYNOTE-B96 study","volume":"36","author":"Colombo","year":"2026","journal-title":"Ann. Oncol."},{"issue":"10496","key":"10.1016\/j.ygyno.2026.06.021_bb0100","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1016\/S0140-6736(25)01040-2","article-title":"Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomized, controlled, phase 3 trial","volume":"405","author":"Olawaiye","year":"2025","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ygyno.2026.06.021_bb0105","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2174\/1389450124666230731094837","article-title":"Microtubules and cell division: potential pharmacological targets in cancer therapy","volume":"24","author":"Sebastian","year":"2023","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ygyno.2026.06.021_bb0110","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.canlet.2016.12.018","article-title":"Metronomic chemotherapy: a potent macerator of cancer by inducing angiogenesis suppression and antitumor immune activation","volume":"400","author":"Biziota","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ygyno.2026.06.021_bb0115","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S1040-8428(02)00109-9","article-title":"Weekly administration of paclitaxel: theoretical and clinical bias","volume":"44","author":"Marchetti","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ygyno.2026.06.021_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.08.1708","article-title":"1068P second progression-free survival (PFS2) and subsequent treatment in patients with folate receptor alpha-positive platinum-resistant ovarian cancer treated with mirvetuximab soravtansine vs investigator\u2019s choice chemotherapy: phase III MIRASOL trial","volume":"36","author":"Moore","year":"2025","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2026.06.021_bb0125","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1158\/1078-0432.CCR-24-3128","article-title":"Randomized phase II study of bevacizumab with weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant\/refractory high-grade ovarian cancer (NCI trial)","volume":"31","author":"Alqaisi","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.ygyno.2026.06.021_bb0130","first-page":"269","article-title":"Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer","volume":"121","author":"O\u2019Malley","year":"2011"},{"key":"10.1016\/j.ygyno.2026.06.021_bb0135","author":"National Comprehensive Cancer Network"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582602041X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582602041X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:35:51Z","timestamp":1786149351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082582602041X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":27,"alternative-id":["S009082582602041X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.06.021","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response to mirvetuximab soravtansine and weekly paclitaxel based on treatment sequencing in platinum-resistant ovarian cancer: Does order matter?","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.06.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}